Compare MasterCard Inc (MA) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Zoetis Inc — how do they compare? MasterCard Inc trades at $560.2 (market cap $491.83B), while Zoetis Inc trades at $73.6 (market cap $31.14B). The key difference: MasterCard Inc is far larger — about 15.8× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| MA | ZTS | |
|---|---|---|
Market Cap | $491.83B | $31.14B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $598.96 | $156.76 |
52-Week Low | $471.55 | $71.91 |
Enterprise Value | $504.86B | $38.70B |
Dividend Yield | 0.62% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $559.88, down 0.58% today, with strong technical support at $559 and resistance at $566. The stock shows robust fundamentals, with Q2 2026 EPS beating expectations at $5.04 versus $4.77, and revenue growth accelerating to $32.79B in 2025. Analysts maintain a bullish consensus, with 79% buy ratings and a $660.85 price target, while institutional buying activity remains positive, as noted in recent SEC filings.
Outlook is positive due to consistent earnings beats, high profitability margins, and strategic initiatives in digital payments and AI. Risks include competition from emerging payment technologies like stablecoins, as highlighted by The Motley Fool on April 10, 2026, and elevated valuation multiples such as a P/E of 30.88, which may limit near-term upside if growth slows.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
